Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing. Meanwhile, the rheumatology world awaits the debut of other ustekinumab biosimilars in the market — and what they may portend for patient care moving forward
Related Keywords
United States , Stephen Hanauer , Byrob Volansky , Stephenb Hanauer , Shenaz Bagha , Janet Franklin , Samsung Bioepis , Clifford Joseph Barborka , Northwestern University Feinberg School Of Medicine , Johnson , Amgen , Weill Cornell Medical College , Digestive Health Center At Northwestern Medicine , Pfizer , Global Development Biosimilars At Amgen , Teva Pharmaceuticals , Global Development Biosimilars , Amelia Bond , Digestive Health Center , Northwestern Medicine , Northwestern University Feinberg School ,
comparemela.com © 2020. All Rights Reserved.